Bill Mcelroy Email & Phone Number

Dublin, Ie

● Constellation Pharmaceuticals was acquired by MorphoSys in July 2021 and is now part of Novartis● Co-led a difficult-to-drug oncology target through HTS campaign that identified two structurally enabled chemical series● Identified CROs and managed productive relationships with their pharmacology and chemistry teams to characterize hits and advance SAR, respectively● Simultaneously co-led a novel epigenetic target at the hit finding stage

● Kintai Therapeutics restructured and became Senda Biosciences in 2020● Led chemistry team focused on identifying microbiome-inspired therapeutics for Parkinson's Disease● Provided chemistry guidance to drive internal exploratory projects and an early external partnership

● Led team that discovered bifunctional Protacs in two distinct chemical series that degraded a protein of interest for an immuno-oncology project● Conceived of and led chemistry effort on a fragment-based screen for a challenging antibacterial program. Led to the discovery of a therapeutic target and accompanying chemical matter

● Responsible for new target identification and validation, identification of tool molecules for early programs, and hit-to-lead efforts to generate in vivo-ready chemical matter● Developed a "gut only" tool molecule to investigate tissue-specific activation of a target leading to a clear decision to terminate the program ● Led SAR activities resulting in orally bioavailable analogues that act on ion channel target for in vivo proof of biology studies● Identified a replacement chemotype from an HTS campaign for a cardiovascular target that had proven resistant to discovery of new chemical matter

● Focused on identification of selective kinase inhibitors for non-oncology indications● Worked up a screening campaign to discover an aminopyrazole chemotype that exhibits a unique binding mode to IRAK4● Used structure-based drug design to progress the hit to a selective and bioavailable inhibitor that was used to validate the program's cellular and in vivo PD assays● Our efforts led to discovery of an orally bioavailable IRAK4 inhibitor that was efficacious in a mouse model of inflammation

Kenilworth, New Jersey, Us

● Responsible for the design and synthesis of biologically active molecules for CNS targets● Pioneered heteroaryl replacements for alicycles for PDE10A inhibitor program. These findings led to discovery of an analogue with both activity in rodent model of disease and cynomolgus exposure

Austin, Tx, Us

Phd, Chemistry

Bs, Chemistry; Minor, Mathematics